Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Publication year range
1.
Infect Genet Evol ; 14: 335-9, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23333774

ABSTRACT

This study was conduced to determinate the seroprevalence and risk factors associated to hepatitis E virus (HEV) exposition, in individuals who work in pig farms located at western of Artemise Province. The presence of HEV in human and swine samples and the phylogenetic analysis were evaluated. One hundred six workers (with an age range of 18-70years) were enrolled in this study. Two groups were defined, 69 employees with swine related occupations and 37 workers without contact with pigs. None had abroad travel history. Serum samples were tested for immunoglobulins (Ig) M, G and A against HEV. Individual fecal samples were obtained from 57 workers and 53 swine. All feces were tested for HEV RNA using reverse transcription PCR (RT-PCR). The amplification products were sequenced and phylogenetically analyzed by using MEGA5 software. A total of 38 (35.8%) (95% CI: 26.2-45.4) sera was positive for antibodies against HEV (anti-HEV). These were higher in persons who work in contact with swine compare as individuals with occupations without pig contact (40.5%, 28/69, 95% CI: 28.2-52.8, versus 27.0%, 10/37, 95% CI: 11.3-42.6, respectively). The prevalence of anti-HEV was higher in workers with an age range of 60-70years old and time-work 10-13years. HEV RNA was detected in 8 (14.0%) of 57 human fecal samples and 10 (18.8%) of 53 swine fecal samples. Phylogenetic analysis was performed on 7 amplification products obtained from 3 human and 4 swine fecal samples. Human and swine HEV sequences were closely related (94-99% nucleotide homology) and belonged to HEV genotype 3, subtype 3a.


Subject(s)
Genotype , Hepatitis E virus/genetics , Adolescent , Adult , Aged , Animals , Female , Hepatitis Antibodies/immunology , Hepatitis E/epidemiology , Hepatitis E virus/immunology , Humans , Male , Middle Aged , Phylogeny , Prevalence , RNA, Viral , Swine , Swine Diseases/epidemiology , Young Adult
2.
Rev. cuba. med. trop ; 51(3): 206-207, Sept.-Dec. 1999.
Article in Spanish | LILACS | ID: lil-333505

ABSTRACT

The results of a study of markers of infection/immunity by hepatitis B virus in a community of the health area in "Cristobal Labra" polyclinics, City of Habana in 1995. The studied healthy adult population was not included in any vaccination strategy with hepatitis B vaccine. Two markers were studied: Hepatitis B surface antigen and its corresponding antibody (anti-HBs). HBsAg-positivity was 1.05% and anti-HBs positivity was 13.39%. Of anti-HBs-positive cases, 13.39% had titers from 10-50 UI/L and the rest (43.68%) had titers over 50 UI/L.


Subject(s)
Humans , Adolescent , Adult , Middle Aged , Hepatitis B , Hepatitis B Antibodies , Hepatitis B virus/immunology , Cuba , Urban Population
3.
Rev. cuba. med. trop ; 51(1): 46-49, ene.-abr. 1999.
Article in Spanish | LILACS | ID: lil-333541

ABSTRACT

The Heberbiovac-HB recombinant hepatitis B vaccine was administered at dosages of 10.5 and 2.5 micrograms in 3 groups of children aged 6-9 with a vaccination schedule at 0, 1 and 6 months of age. The immunogenecity attained between dosages was compared. The seroconversion with protective titres obtained at 2 months varied from 88.9 with 10 micrograms to 79.4 with 2.5 micrograms, whereas at 7 months it was higher than 98 in the 3 groups. The geometrical mean with 10 mg was 136.63 and 2,356.8 UI/L-1; with 5 micrograms, 77.62 and 1,958.9 UI/L-1; and with 2.5 micrograms, 32.15 and 376.3 UI/UL-1, at 2 and 7 months, respectively. A high immunogenic power of the vaccine is observed at dosages of 10 and 5 micrograms with similar results. In spite of the fact that the dosage of 2.5 micrograms is immunogenic, the response is not desirable. These results state the possibility of using a lower dosage (5 micrograms) for a low risk infantile population, which favors the cost-benefit.


Subject(s)
Humans , Male , Female , Child , Hepatitis B Vaccines , Vaccines, DNA , Hepatitis B Vaccines , Time Factors , Vaccines, DNA
SELECTION OF CITATIONS
SEARCH DETAIL
...